Wu and colleagues provide a fascinating insight into the potential role of nitrates in aggressive prostate cancer (1) with the suggestion that higher nitrates might be beneficial. Wu and colleagues also draw attention to the emerging relation of higher nitrates with lower cardiovascular disease risk (1). Despite a meticulously conducted study, the authors are rightly cautious in interpreting their novel findings and do not place undue weight on any potential mechanistic pathway. Nevertheless, it is intriguing to note that nitrates are thought to be endocrine disruptors whose administration has been shown to decrease testosterone production in male rats (2). Antiandrogens are a keystone of prostate cancer treatment, even at castrate levels of serum testosterone (3). Moreover, despite the creation of a positive climate of opinion concerning androgen replacement therapy (4), it has nonetheless, eventually, come to light that androgen replacement causes cardiovascular events (5). Androgens as a factor in both prostate cancer and cardiovascular disease would provide a parsimonious, unifying explanation for disparate observations (1), as well as offering the promise of providing an organizing principle for dietary advice and new directions for the prevention and treatment of two of the most common and serious diseases among men. To what extent such possibilities could be relevant to the current program of reducing nitrates in drinking water remains to be determined.

No potential conflicts of interest were disclosed.

1.
Wu
T
,
Wang
Y
,
Ho
SM
,
Giovannucci
E
. 
Plasma levels of nitrate and risk of prostate cancer: a prospective study
.
Cancer Epidemiol Biomarkers Prev
2013
;
22
:
1210
8
.
2.
Panesar
NS
,
Chan
KW
. 
Decreased steroid hormone synthesis from inorganic nitrite and nitrate: studies in vitro and in vivo
.
Toxicol Appl Pharmacol
2000
;
169
:
222
30
.
3.
Scher
HI
,
Fizazi
K
,
Saad
F
,
Taplin
M-E
,
Sternberg
CN
,
Miller
K
, et al
Increased survival with enzalutamide in prostate cancer after chemotherapy
.
N Engl J Med
2012
;
367
:
1187
97
.
4.
Braun
SR
. 
Promoting “Low T”
.
JAMA Intern Med
2013
:
1
4
.
doi:10.1001/jamainternmed.2013.6892.
5.
Xu
L
,
Freeman
G
,
Cowling
BJ
,
Schooling
CM
. 
Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials
.
BMC Med
2013
;
11
:
108
.